Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye-Reference-Cited by-同舟云学术

Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye

Published:2023-12-28 Issue:4 Volume:40 Page:242-250
ISSN:1300-7777
Container-title:Turkish Journal of Hematology
language:
Short-container-title:Tjh

Author:

Tekinalp Atakan,Gedük Ayfer,Akdeniz Aydan,Terzi Demirsoy Esra,Gürsoy Vildan,Aslaner Ak Müzeyyen,Bağcı Metin,Seçilmiş Sema,Keklik Karadağ Fatma,Oruç Uysal Ayşe,Doğan Ali,Demircioğlu Sinan,Erol Haşim Atakan,Aslan Ceyda,Özkalemkaş Fahir,Ertop Şehmus,Dağlı Mehmet,Dal Mehmet Sinan,Saydam Güray,Merter Mustafa,Ural Cihan,Çeneli Özcan

Publisher

Galenos Yayinevi

Subject

Hematology

Reference25 articles.

1. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management;Rajkumar;Am J Hematol,2020

2. 2. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328-346.

3. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era;Zhou;Blood,2014

4. CD38: A target for immunotherapeutic approaches in multiple myeloma;Morandi;Front Immunol,2018

5. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking;Overdijk;J Immunol,2016